TALTRIMIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H16N2O4S
Molecular Weight	296.342
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)NS(=O)(=O)CCN1C(=O)C2=CC=CC=C2C1=O

InChI

InChIKey=NZKNHIQZWSVJGP-UHFFFAOYSA-N

InChI=1S/C13H16N2O4S/c1-9(2)14-20(18,19)8-7-15-12(16)10-5-3-4-6-11(10)13(15)17/h3-6,9,14H,7-8H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C13H16N2O4S
Molecular Weight	296.342
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3143554 | https://www.ncbi.nlm.nih.gov/pubmed/3031533 | https://adisinsight.springer.com/drugs/800007910

Taltrimide, a taurine derivative that was developed as an anticonvulsive agent. Taltrimide strongly inhibits the sodium-independent binding of taurine to synaptic membranes of the brain and it does not appear to bind to GABAA and benzodiazepine receptor. The drug was studied in phase II clinical trial Finland as an anticonvulsant agent to treat epilepsy. However, the further development of this drug was discontinued.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glycine receptor 13 Target ID: CHEMBL3392921 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3437979 \| https://www.ncbi.nlm.nih.gov/pubmed/3031533	Binding Agent 1076		68.0 nM [Ki]

PubMed

Title	Date	PubMed
A controlled study with taltrimide and sodium valproate: valproate effective in partial epilepsy.	1990-08	2124033
Effects of taltrimide, an experimental taurine derivative, on photoconvulsive response in epileptic patients.	1987-03-01	3816708
Effects of the anticonvulsant taurine derivative, taltrimide, on membrane transport and binding of GABA and taurine in the mouse cerebrum.	1987-01	3031533
The anticonvulsive actions of two lipophilic taurine derivatives.	1985	20492992

Patents

Sample Use Guides

In Vivo Use Guide

in daily doses of 1 and 2 g for 2 weeks with an interval of 2.5 months in 2 phase I clinical trials to 9 drug-resistant epileptic patients.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:30:15 GMT 2025` Edited by `admin` on `Wed Apr 02 09:30:15 GMT 2025`
Record UNII	NQ74U9QR5D
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TALTRIMIDE

Official Name

English

taltrimide [INN]

Preferred Name

English

Classification Tree Code System Code

NCI_THESAURUS

C264